Pramlintide (Triproamylin, pramlintida, TRIPRO-AMYLIN) is classified under amylin analogs. Research goals associated with it include metabolic & weight.

Is Pramlintide FDA-approved?

The regulatory status of Pramlintide is not established in our sources.

What does the research on Pramlintide say?

peptideone aggregates 8 references from PubMed for Pramlintide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.

← All peptides

Pramlintide

Status unknown

Also known as: Triproamylin, pramlintida, TRIPRO-AMYLIN, AC0137, AC137, AC-137, AC-0137, D3FM8FA78T

Pramlintide (Triproamylin, pramlintida, TRIPRO-AMYLIN) is classified under amylin analogs.

What the research says

Aggregated from the cited literature below. We summarize sources — we don't author claims.

Pramlintide is a synthetic analogue of the human hormone amylin and is described as an amylinomimetic compound. Review literature reports that it is used clinically as an adjunct to insulin therapy for type 1 and type 2 diabetes, and that amylin agonists (including pramlintide) have been investigated for potential weight-loss effects in obesity research, including in combination with other agents. (PMIDs: 26071095, 16278328, 34288673, 30000033, 39317404)

Mechanism (as reported)

A review describes amylin as activating specific multisubunit G protein-coupled receptors (with multiple receptor subtypes) and functioning in glucoregulatory energy metabolism and other reported organ-system effects. (PMID: 26071095) A pramlintide-focused review reports that pramlintide complements insulin’s effects in postprandial glucose regulation by decreasing glucagon secretion; it is also reported to slow gastric emptying and reduce postprandial glucose levels. (PMID: 16278328)

Key findings (each cites a source)

Pramlintide is described as a synthetic analogue of the human hormone amylin and as an amylinomimetic compound. (PMID: 16278328) [PMID 16278328]
Amylin is described as a 37-amino-acid peptide that activates specific multisubunit G protein-coupled receptors, resulting in multiple receptor subtypes. (PMID: 26071095) [PMID 26071095]
A review reports that pramlintide is used clinically to treat type 1 and type 2 diabetes. (PMIDs: 26071095, 16278328) [PMID 26071095, 16278328]
A review reports that pramlintide is used as an adjunct to insulin therapy for patients with diabetes who have failed to achieve glycemic control despite optimal insulin therapy. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports that pramlintide decreases glucagon secretion and complements insulin’s effects in postprandial glucose regulation. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports pramlintide slows gastric emptying and reduces postprandial glucose levels. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports that pramlintide is predominantly renally eliminated and has a mean elimination half-life of about 30–50 minutes. (PMID: 16278328) [PMID 16278328]
A pramlintide review reports an increased risk of insulin-induced severe hypoglycemia, along with adverse events such as nausea, anorexia, fatigue, and vomiting. (PMID: 16278328) [PMID 16278328]
A review reports that clinical studies in obesity indicate amylin agonists (including pramlintide) could be useful for weight loss, especially in combination with other agents. (PMID: 26071095) [PMID 26071095]
A source describing amylin analogs for obesity reports that pramlintide has demonstrated weight-lowering action and that clinical trials confirmed weight loss exceeding 3% during the study period, maintained beyond follow-up, without major untoward effects (as characterized in that source). (PMID: 39317404) [PMID 39317404]
A source on longer-acting amylin analogue development reports that pramlintide is commercially available for diabetes treatment but requires three daily injections due to short half-life, motivating development of a longer-acting analogue (cagrilintide). (PMID: 34288673) [PMID 34288673]

Independent test grades

No independent third-party test data is available for Pramlintide yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.

Research literature (8)

Consolidated from PubMed — each links to the original record.

Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance.
Apostolopoulou M, Lambadiari V, Roden M, Dimitriadis GD · Endocrine reviews · 2025 · PMID 39998445
Amylin analogs for the treatment of obesity without diabetes: present and future.
Panou T, Gouveri E, Popovic DS, Papanas N · Expert review of clinical pharmacology · 2024 · PMID 39317404
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R · JAMA · 2022 · PMID 35015037
Development of Cagrilintide, a Long-Acting Amylin Analogue.
Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C · Journal of medicinal chemistry · 2021 · PMID 34288673
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C · JAMA · 2021 · PMID 33755728
Amylin: Pharmacology, Physiology, and Clinical Potential.
Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD · Pharmacological reviews · 2015 · PMID 26071095
Pramlintide.
2006 · PMID 30000033
Pramlintide acetate.
McQueen J · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2005 · PMID 16278328

FAQ

What is Pramlintide?: Pramlintide (Triproamylin, pramlintida, TRIPRO-AMYLIN) is classified under amylin analogs. Research goals associated with it include metabolic & weight.
Is Pramlintide FDA-approved?: The regulatory status of Pramlintide is not established in our sources.
What does the research on Pramlintide say?: peptideone aggregates 8 references from PubMed for Pramlintide. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.

Quick facts

Chemical identity from PubChem.

Molecular formula: C171H267N51O53S2
Molecular weight: 3949 g/mol
CAS number: 151126-32-8
PubChem CID: 70691388
InChIKey: TZIRZGBAFTZREM-MKAGXXMWSA-N
SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)N
Regulatory status: Status unknown